An iron-containing, tetrapyrrole ring, heme is an essential prosthetic group in an array of proteins that comprehensively affect cellular function and metabolism; yet "free" heme in sufficient amounts can be damaging to the kidney and other organs because of its bioreactivity and pro-oxidant effects. This review discusses the cellular metabolism of heme in health and disease and covers such areas as the synthesis of heme and its utilization in heme proteins; mechanisms underlying the toxicity of heme; and the extent to which pathophysiologic processes, such as renal incorporation of heme proteins or destabilization of intracellular heme proteins, increase intracellular levels of heme and provoke renal injury. The main catabolic process that degrades heme, the heme oxygenase (HO) system, is reviewed, and evidence for the protective effects of HO-1 against acute and chronic heme/heme protein-induced renal injury is summarized. Finally, current views regarding the molecular basis for heme-induced upregulation of HO-1 are discussed.
T he tetrapyrrole heme molecule possesses such biologically beneficial properties as the ability to bind oxygen, nitric oxide, and carbon monoxide, and the capacity to transfer electrons (1) (2) (3) . Heme in its free, unfettered form, however, is potentially toxic and relatively insoluble. Heme proteins thus represent a clever strategy in that they capitalize on the biologically useful properties of heme in carrying out their specific function, and by linking heme to a given protein moiety, heme proteins circumvent such issues as the potential toxicity and insolubility of "free" heme (4) .
The functional significance of heme is far-ranging as heme proteins number in the hundreds and are found in all cellular compartments (1) (2) (3) . In addition to hemoglobin and myoglobin, heme proteins include mitochondrial cytochromes that use the heme group in electron transfer and in generating a proton gradient; cytochrome P450 enzymes that metabolize potentially toxic endogenous and exogenous substances; enzymes such as nitric oxide synthase, guanylate cyclase, and prostaglandin synthase that influence, among other functions, vascular tone; phosphodiesterases that regulate levels of cyclic nucleotides and thus their involvement in cell signaling; antioxidant enzymes such as catalase and peroxidases; oxidant-generating enzymes such as NADPH oxidase; and certain regulators of transcription and translation. Moreover, because of their ability to bind oxygen, nitric oxide, and carbon monoxide, heme proteins can serve as heme-based sensors that enable cells to monitor and respond appropriately to changes in their local milieu.
The physiology and pathophysiology of heme is germane to iron metabolism and kidney disease for several reasons. First, free heme in relatively large amounts can be toxic to the kidney and other organs and provides a pathway for kidney disease in certain settings (5, 6) . Second, heme, especially heme that is present in the cytochrome P450 system, may serve as a source of iron that drives oxidant injury after hypoxic and nephrotoxic insults (7, 8) . Third, it was in the course of studies that examined the renal adaptive response to heme and heme proteins that evidence was first derived in 1992 demonstrating the cytoprotective nature of heme oxygenase-1 (HO-1) (9), the latter providing a therapeutic strategy for kidney and other diseases (1,10 -13) . Fourth, HO-1 is now recognized as an important participant in maintaining iron homeostasis in health and disease (9,14 -17) . Figure 1 provides an overview of physiologic and pathophysiologic processes that broadly influence cellular levels of heme. All nucleated cells synthesize heme, a process that begins and ends in the mitochondrion (1-3). Glycine and succinyl-CoA condense to form ␦-aminolevulinic acid (ALA) under the catalytic effect of the mitochondrial enzyme ALA synthase. In the cytosol, ALA serves as the starting substrate for a series of enzyme-catalyzed reactions that sequentially generate porphobilinogen, hydroxymethylbilane, uroporphyrinogen III, and finally coproporphyrinogen III. In the mitochondrion, coproporphyrinogen III is oxidatively decarboxylated to protoporphyrin IX, into which iron is inserted via a ferrochelatase-catalyzed reaction, the latter resulting in the formation of heme. In the kidney and other tissues, heme exerts feedback inhibition on ALA synthase, the rate-limiting enzyme in the synthesis of heme.
Cellular Metabolism of Heme in Health and Disease
The synthesis of heme in the kidney is notable in the following ways (18) : First, the cortex, especially the proximal tubule, possesses a greater heme-synthesizing capacity as compared with the medulla, and such disposition of heme-synthesizing ability closely overlaps with that exhibited by the cytochrome P450 system. Second, ALA synthase in the kidney, as compared with the liver, may be less modifiable by exogenous stimuli. It has been suggested that these two features render the renal heme-synthesizing machinery relatively impervious to the inhibitory effect of substances detoxified or excreted by the kidney, thereby securing a steady supply of heme for incorporation into heme proteins, including those that are involved in the cytochrome P450 system (18) .
Pathophysiologic processes also may contribute to increased levels of heme in the kidney (Figure 1 ). Ischemic and nephrotoxic insults may destabilize intracellular heme proteins normally present in the kidney, thereby incurring increased intracellular levels of heme (19, 20) . Increased renal content of heme also may occur as heme proteins that are extrinsic to the kidney (e.g., myoglobin from injured muscle, hemoglobin from lysed erythrocytes) are delivered to and incorporated by the kidney via the megalin/cubulin receptors (5, 6) . After oxidation and destabilization of these heme proteins, heme ultimately is freed, and thus accrues within cells. The lipophilic nature of heme enables permeation of cell membranes by heme and cellular distribution of heme via the intracellular canalicular system (21).
The catabolism of heme is effected by HO (Figure 1 ) (1,10 -13) . In a process that uses oxygen and NADPH, HO catalyzes the conversion of heme to biliverdin, during which iron is released and CO is generated; biliverdin is metabolized to bilirubin by biliverdin reductase. HO activity is exhibited by two isozymes. HO-1 is the isozyme that is upregulated in stressed organs and tissues, and is induced by a diverse array of stimuli, including hypoxia, ischemia, hyperoxia, oxidative stress, proinflammatory stress, and heavy metals. HO-1 is expressed weakly in renal tubules in the unstressed kidney but can be induced strongly in renal tubules and arterioles by stressors such as heme and certain metals (22) . HO-2 is the constitutive isozyme that accounts for the bulk of HO activity in the kidney in health and is expressed in the preglomerular vasculature, the thick ascending limb, and the distal nephron (22) . The induction of HO-1, at least in distal nephron-derived cells, is more robust after basolateral as compared with apical exposure to heme, and such induction is accentuated by pathophysiologically relevant stimuli such as hypoxia and hepatocyte growth factor (23).
Toxicity of Heme
Cellular levels of free heme are approximately 100 nM or less (1) (2) (3) 24) . Higher amounts can be injurious, as demonstrated by a large body of evidence (1-6,24 -29) . For example, in low micromolar amounts and in serum-deficient conditions, heme induces caspase-3 expression and apoptosis (4) . In the presence of serum (which itself promotes cell survival), such concentrations of heme do not induce apoptosis or cell detachment from the cell monolayer but rather upregulate the cell-cycle inhibitor p21, induce cell-cycle arrest, and inhibit proliferative cell growth. Such effects of heme may contribute to the previously Figure 1 . This schema provides an overview of cellular metabolism of heme in health and disease in the kidney. Pathways in red indicate the major mechanisms that influence cellular levels of heme.
recognized antiproliferative effects of heme proteins such as myoglobin (30) . The nephrotoxic capability of heme is also clinically observed as the administration of comparatively large quantities of hematin to suppress porphyrin synthesis in patients with acute intermittent porphyria may incur oliguric acute renal failure (29) .
Multiple mechanisms can contribute to the toxic effects of relatively large amounts of heme (1-6,24 -29) . In plasma and intracellular membranes, heme can oxidize lipid, denature proteins, and perturb the integrity of the attached cytoskeleton. Heme also may impair the activity of cytosolic enzymes, including certain glycolytic enzymes, glucose-6-phosphate dehydrogenase, and glutathione reductase; conversely, heme may activate cell-damaging enzymes such as caspases and cathepsins. Heme also can oxidatively denature DNA in vitro. The mitochondrion is particularly vulnerable to the toxicity of heme: Mitochondria, exposed to heme in pathophysiologically relevant amounts, exhibit a prompt increase in respiration followed by a decline and then a complete cessation in oxygen consumption (27) . Such susceptibility to heme may reflect the facile permeation of the lipid-rich, mitochondrial membranes by heme, whereas the relatively small amounts of peroxides normally generated in the course of mitochondrial respiration may exacerbate the pro-oxidant and other damaging effects of heme on these organelles (27) . In this regard, increased yet nontoxic amounts of heme and hydrogen peroxide, when present concomitantly, can prove remarkably cytolytic. Peroxides can degrade heme and promote the release of iron, the latter recently shown to induce directly mitochondrial and cellular release of cytochrome c (31). Finally, low micromolar amounts of heme can stimulate cellular generation of hydrogen peroxide by renal tubular epithelial cells (26) .
In addition to its direct cytotoxicity, heme can induce renal injury by its proinflammatory effects (28,32-34). For example, in renal tubular epithelial cells and in the kidney in vivo, heme potently induces chemokines such as monocyte chemoattractant protein-1 (MCP-1) by activating its redox-sensitive transcription factor NF-B (32, 33) . The administration of heme in vivo upregulates expression of adhesion molecules in organs such as the gut, liver, and pancreas, and such expression is attended by leukocytic recruitment and increased vascular permeability (34).
HO-1 as a Protectant against Heme/Heme Protein-Induced Renal Injury
Studies in 1989 identified HO as the 32-kD protein induced in stressed cells and queried whether such induction of HO-1 was a protective response (35) . Such cytoprotection would arise, as subsequently was hypothesized in 1990, from two complementary effects (24) : The dissipation of heme, a pro-oxidant, and the attendant generation of bilirubin, a metabolite with antioxidant properties (36) . To examine this hypothesis, the glycerol model of heme protein-induced acute renal failure was used (9) . The intramuscular injection of hypertonic glycerol induces myolysis and hemolysis, thereby imposing a large burden of heme proteins and, ultimately, heme, on the kidney (5,6). Heme proteins and/or heme is involved in each of the main mechanismsvasoconstriction, nephron cast formation, and direct cytotoxicity-that account for acute kidney injury in this model (5, 6) . After the administration of glycerol, HO-1 mRNA and HO activity were induced robustly, and the inhibition of HO activity, although not affecting renal function in rats with intact kidneys, significantly worsened renal function in glycerol-injected rats (9) . In complementary studies, the prior induction of HO-1 by "conditioning" the kidney by exposure to small amounts of hemoglobin (9), endotoxin (37), or nephrotoxic serum (38) also conferred protection against glycerol-induced acute renal failure, as did hyperbilirubinemia, the latter achieved by bile duct ligation (39) . In addition, mutant mice that are unable to express HO-1 exhibit markedly increased sensitivity to heme proteins as evidenced by heightened renal injury, accumulation of heme, and increased mortality when subjected to the glycerol model or hemoglobin (40) .
The protective effect of HO-1 that is observed in the glycerol model is supported by studies in other model systems. For example, endothelial cells that are transfected with the human HO-1 gene are resistant to heme/hemoglobin-induced injury (41) . Heme-induced apoptosis of tubular epithelial cells is exacerbated when HO activity is inhibited (4). Upregulation of HO-1 in basilar arteries by gene transfer attenuates hemoglobin-induced vasoconstriction, and this effect is abrogated when HO activity is inhibited concomitantly (42) . Finally, patients unable to genetically express HO-1 accumulate heme in plasma and develop kidney and other diseases (43) .
Studies in the glycerol model also revealed that synthesis of the iron-sequestering protein, ferritin, was linked to expression of HO-1: Concordant changes in renal ferritin content occurred as HO activity was modulated in this model (9) . Ferritin is a highly efficient cellular storage site for iron, and ferritin H chain exhibits ferroxidase activity, which inhibits the redox cycling of iron (14) . These combined effects of ferritin thus reduce the risk for iron-catalyzed oxidative stress, and evidence that such actions of ferritin contribute to the cytoprotective effects of HO-1 was provided in studies of oxidant-mediated toxicity in vitro (14) . Upregulation of HO-1 also elicits the synthesis of ironexporting proteins, as shown in studies in the glycerol model (16) , whereas analyses of the HO-1 Ϫ/Ϫ mouse uncovered the fundamental participation of HO-1 in homeostasis of iron (15) . The likelihood that oxidative stress and injury are driven by iron released from heme is thus minimized by coupling the induction of HO-1 to the synthesis of iron-storage and ironexporting proteins. Renal inflammation and tubular induction of HO-1 occur in rodent kidneys that are exposed repetitively to heme proteins (44) and in diseased human kidneys that are exposed intermittently to heme proteins, as occurs in glomerulopathies, sickle cell nephropathy, and paroxysmal nocturnal hemoglobinuria (13, 45) . To examine the significance of induction of HO-1 in the kidney chronically exposed to heme proteins, HO-1 ϩ/ϩ and HO-1 Ϫ/Ϫ mice were administered hemoglobin at weekly intervals (32) . Renal responses to hemoglobin were exaggerated in mice that were unable to express HO-1: HO-1 ϩ/ϩ mice displayed mild tubulointerstitial inflammation, whereas HO-1
mice exhibited striking interstitial inflammation accompanied by marked renal induction of the chemokine MCP-1, along with exaggerated activation of its redox-sensitive transcription factor NF-B (32) . The deficiency of HO-1 thus facilitates the activation of NF-B and the attendant upregulation of NF-B-driven cytokines such as MCP-1. HO-1 thus exerts anti-inflammatory effects, at least in part, by suppressing activation of proinflammatory transcription factors and cytokines (32) . Table 1 summarizes the salient cellular effects of products of HO relevant to cytoprotection (1,10 -13,46) . CO can induce vasorelaxation by stimulating cGMP and calcium-activated potassium channels (12, 46) ; CO may confer anti-inflammatory effects by stimulating p38 mitogen-activated protein kinase (46) , and by inhibiting generation of endothelin-1 and PDGF (47); anti-apoptotic effects of CO may accrue from upregulation of p38 mitogen-activated protein kinase (46) and, possibly, p21 (4, 48) . Iron can induce iron-binding as well as iron-exporting proteins, HO-1, p21, and genes that are relevant to cell growth. Bile pigments are potent antioxidants by scavenging oxidants and decreasing the activity of NADPH oxidase (12, 36) ; bile pigments also could inhibit extracellular signal-regulated kinase activation (49) . Through such combined effects, products of HO-1 may contribute to the cytoprotective effects of HO-1.
Cellular Effects of Products of HO

Molecular Basis for Induction of HO-1 by Heme in Renal Tubular Epithelial Cells
Under homeostatic conditions, the HO-1 gene (hmox1) is under active repression by the transcription regulator Bach1, as evidenced by the spontaneous upregulation of HO-1 expression in multiple organs of Bach1-deficient mice relative to those of wild-type animals (50) . Bach1, in a heterodimeric complex with small Maf proteins, binds to the so-called stress-response elements (StRE) within the upstream enhancer loci of the hmox1 gene. Because neither Bach1 nor small Maf proteins harbor canonical transcription activation domains, such binding imposes gene repression. An interesting characteristic of Bach1 is that it binds heme with high affinity, at least in vitro. This association with heme alters the DNA-binding property of Bach1, resulting in reduced affinity of Bach 1 for the StRE. These observations suggest a simple model for induction of HO-1 expression: Inactivation of Bach1-mediated hmox1 gene repression by increased cellular levels of heme (51) . In some tissues of Bach1-deficient mice, however, maximal expression of HO-1 also requires the presence of Nrf2, a protein that belongs to the same subfamily of transcription regulators as does Bach1. Like Bach1, Nrf2 forms heterodimers with small Maf proteins that also can bind to the StRE. Unlike Bach1, however, Nrf2 contains a potent transcription activation domain and Nrf2⅐Maf dimers function as transcription activators rather than repressors. Recent studies in rat renal tubular epithelial cells have shown that heme stimulates expression of the transcription factor Nrf2, and inhibition of Nrf2 activity abolishes the heme-dependent transcription activity of the hmox1 enhancer (52) . Collectively, these observations suggest that optimal hmox1 gene activation by heme in renal tubular epithelial cells involves both inactivation of Bach1-mediated repression and stimulation of Nrf2-dependent transcription. At the molecular level, this process presumably requires, as previously postulated (50), the displacement of Bach1⅐Maf dimers from the StRE followed by occupancy by Nrf2⅐Maf complexes.
Other transcription factors also have been proposed to regulate hmox1 transcription in response to heme. For instance, heme stimulates the DNA-binding activity of the redox-sensitive transcription factor NF-B (53), presumably via its direct pro-oxidant effects or through iron that is released during heme catabolism as shown in renal epithelial cells (33) . In addition, specific inhibition of NF-B activity by overexpression of a proteasomal-resistant IB mutant attenuates cadmium-and heme-induced HO-1 accumulation in other cell types (54) . Although the latter studies in particular provide compelling evidence for a role of NF-B in regulation of HO-1 expression, to date, a functional NF-B binding site has not been identified convincingly in the regulatory region of hmox1 genes of any species. In the absence of such regulatory elements, it is reasonable to speculate that NF-B modulates hmox1 gene transcription by indirect, rather than direct, mechanisms possibly in cooperation with other DNA-binding proteins, as has been postulated for several NF-B-dependent genes (55) . For instance, induction of the keratin 6b gene by TNF-␣ requires both NF-B and the transcription factor CCAAT/enhancer binding protein ␤ (C/EBP␤) because downregulation of either factor abolishes the response. Such activation, however, does not necessitate NF-B/DNA interaction but rather depends on three tandem C/EBP binding sites that serve as targets for a presumptive NF-B⅐C/EBP␤ complex (56) . Of note, the mouse hmox1 gene contains C/EBP␤ binding sites in close proximity to the StRE that contribute to gene regulation by cadmium (57) , but their role in regulation by heme has not been examined.
Recent studies in human kidney epithelial (HK-2) cells have provided evidence for a role of the upstream stimulatory factors (USF1 and USF2) in hmox1 gene regulation by heme (58) . These proteins differ from Nrf2 and NF-B in that their DNAbinding activities are not stimulated by heme; indeed, in HK-2 cells, USF1 and USF2 bind constitutively to an E-box element immediately upstream of the transcription start site of the hmox1 gene. Nonetheless, mutation of the E-box significantly diminishes the heme-dependent transcription activity of the promoter. It is interesting that, although necessary, the E-box is not sufficient for heme-responsiveness and a larger region of the human hmox1 promoter that contains the StRE orthologues is required for induction (58, 59) . This suggests that USF1 and/or USF2 cooperates with other DNA-binding proteins to promote full gene activation. The identity of these factors has not yet been established but conceivably could include Nrf2, Bach1, or both.
Induction of hmox1 gene expression by various stimuli commonly involves oxidative stress and redox-sensitive pathways, but the mechanisms are complex and depend on the applied stimulus, the tissue and cell type involved, and the species from which cells were derived. The multiplicity of transcription factor pathways that are involved in hmox1 regulation by even the most prototypical HO-1 inducer (i.e., heme) is a clear testament to this complexity.
Conclusion
Current understanding of the cellular physiology of heme in the kidney is inchoate, and the following are among the areas that require elucidation: Characterization of heme metabolism in glomeruli and specific nephron segments; the levels of free, uncommitted heme in healthy kidney cells; the manner by which heme is transferred from its mitochondrial site of synthesis so as to conjoin with specific protein moieties and the subsequent dispersal of these myriad heme proteins to their appropriate cellular loci; the functional significance of renal expression, albeit weak, of heme carrier protein 1, a recently discovered intestinal protein required for the absorption of dietary heme-iron (60); and, finally, the extent to which free heme, either directly or indirectly through HO-generated products, contributes to the functioning of the healthy kidney. With regard to the latter consideration, heme can influence transport activity in other polarized epithelia such as enterocytes (61) , and evidence is accumulating that products of heme, generated by HO, such as CO, can alter tubular and hemodynamic function of the kidney.
From a pathophysiologic perspective, there is an inescapable irony and duality to heme and heme proteins: Truly indispensable for cell survival and function, yet they can become agents of injury. Heme, the molecular motif that is used ubiquitously by proteins involved in so many aspects of cell function, can damage cells when freed from its binding protein and present in excessive amounts; hemoglobin or myoglobin, proteins vitally involved in oxygen transport and storage, can injure the kidney; and cytochrome c, a heme protein that critically contributes to mitochondrial respiration yet, when translocated into the cytosol, can activate caspases and trigger apoptosis.
Finally, from a therapeutic standpoint, the metabolism of heme through HO may instigate cytoprotective pathways that can interrupt disease processes in the kidney and other organs. In this regard and relevant to this Frontiers in Nephrology series, concerns have been raised recently regarding the potential toxicity of parenteral preparations of iron (62, 63) , the latter of established efficacy and benefit in the therapy of iron-deficiency anemia. Interestingly, these preparations also induce HO-1 (64) . It is intriguing whether such induction of HO-1 provides a countervailing response that mitigates the risk for toxicity resulting from the use of parenteral iron or confers a beneficial effect of parenteral iron independent of the correction of anemia.
